AccuStem Sciences appoints Wendy Blosser as CEO with $425k salary and options

Accustem Sciences Inc.

Wendy Blosser appointed CEO effective March 4, 2022.
Base salary of $425,000 per year; eligible for annual bonus of 45% of base, with $47,813 guaranteed in Q1 2022.
Initial stock option award of 490,000 shares at $2.13 exercise price, subject to board approval.
50% of options vest over 4 years; 25% upon $30M equity fundraise; 25% upon CLIA lab launch by Q4 2023.
Employment is at-will; offer contingent on background check and restrictive covenant agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Wendy Blosser

Chief Executive Officer

ACUT · Accustem Sciences Inc.

Effective: 2022-03-04
Filed: March 10, 2022, 6:59 PM ET

Pursuant to an agreement dated February 18, 2022 (the “Offer Letter”), Wendy Blosser was appointed Chief Executive Officer of AccuStem Sciences, Inc. effective March 4, 2022 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Wendy Blosser was appointed as Chief Executive Officer at Accustem Sciences Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Pursuant to an agreement dated February 18, 2022 (the “Offer Letter”), Wendy Blosser was appointed Chief Executive Officer of AccuStem Sciences, Inc. effective March 4, 2022 (the “Effective Date”).

View on SEC.gov

Accustem Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-006524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.